Novel Arylimidamides for Treatment of Visceral Leishmaniasis

Arylimidamides (AIAs) represent a new class of molecules that exhibit potent antileishmanial activity (50% inhibitory concentration [IC(50)], <1 μM) against both Leishmania donovani axenic amastigotes and intracellular Leishmania, the causative agent for human visceral leishmaniasis (VL). A syste...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wang, Michael Zhuo, Zhu, Xiaohua, Srivastava, Anuradha, Liu, Qiang, Sweat, J. Mark, Pandharkar, Trupti, Stephens, Chad E., Riccio, Ed, Parman, Toufan, Munde, Manoj, Mandal, Swati, Madhubala, Rentala, Tidwell, Richard R., Wilson, W. David, Boykin, David W., Hall, James Edwin, Kyle, Dennis E., Werbovetz, Karl A.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology (ASM) 2010
Matèries:
Experimental Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2876428/
https://ncbi.nlm.nih.gov/pubmed/20368397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00250-10
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars